FDA Failed In Alzheimers Drug Approval, Congressional Report Says

According to the staff report, which showed the findings of two committees under the House of Representatives, the approval process for Aduhelm was "rife with irregularities." Most notably, the report revealed that the FDA went against recommendations and accelerated the drug's approval despite data suggesting its ineffectiveness. The investigation, conducted by the Staffs of the Committee on Oversight and Reform and Committee on Energy and Commerce, ran over the course of 18 months and examined the drug's regulatory review and approval, pricing, and marketing. The committees found that the FDA...